Denali Therapeutics
DNLI
194 hedge funds and large institutions have $2.24B invested in Denali Therapeutics in 2023 Q3 according to their latest regulatory filings, with 29 funds opening new positions, 77 increasing their positions, 57 reducing their positions, and 36 closing their positions.
195% more call options, than puts
Call options by funds: $2.06M | Put options by funds: $697K
35% more repeat investments, than reductions
Existing positions increased: 77 | Existing positions reduced: 57
0.19% more ownership
Funds ownership: 78.86% → 79.06% (+0.19%)
4% less funds holding
Funds holding: 203 → 194 (-9)
19% less first-time investments, than exits
New positions opened: 29 | Existing positions closed: 36
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
29% less capital invested
Capital invested by funds: $3.18B → $2.24B (-$938M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BBA
Baker Bros. Advisors
New York
|
+$21.2M |
| 2 |
BlackRock
New York
|
+$19.8M |
| 3 |
WP
Woodline Partners
San Francisco,
California
|
+$18.8M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$9M |
| 5 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
+$7.82M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$14M |
| 2 |
WA
Wasatch Advisors
Salt Lake City,
Utah
|
-$13M |
| 3 |
Man Group
London,
United Kingdom
|
-$12.8M |
| 4 |
Millennium Management
New York
|
-$9.13M |
| 5 |
GGHC
Gilder Gagnon Howe & Co
New York
|
-$8.47M |
DNLI Hedge Fund Activity: Q3 2023 in Review
194 of the 6,310 institutional investors tracked by Wall St. Rank reported a position in Denali Therapeutics (DNLI) for Q3 2023, worth a combined $2.24B — down 29% from $3.18B a quarter earlier.
Sellers outnumbered buyers: 36 funds closed out of DNLI and 29 opened new positions — a net loss of 7 holders — while 57 trimmed existing stakes and 77 added.
The largest buyer was Baker Bros. Advisors, adding an estimated $21.2M. The largest seller was T. Rowe Price Associates, cutting an estimated $14M.
- 194 institutional investors held Denali Therapeutics (DNLI) as of Q3 2023, down from 203 in Q2 2023.
- Funds reported $2.24B of Denali Therapeutics stock for Q3 2023, down 29% quarter-over-quarter.
- 29 funds opened new Denali Therapeutics positions in Q3 2023 and 36 closed out, a net change of -7 holders.
- The largest Denali Therapeutics buyer in Q3 2023 was Baker Bros. Advisors, an estimated $21.2M added.
- The largest Denali Therapeutics seller in Q3 2023 was T. Rowe Price Associates, an estimated $14M sold.
Based on aggregated 13F filings for Q3 2023.